Proteome Systems Ltd.

News & Analysis

proteome systems ltd. - All News and Analysis

• Proteome Systems Renamed Tyrian Diagnostics

  - 2008-11-14

  Completes Transition to Biomarker Discovery and Diagnostic Test Development Company SYDNEY, Australia -- Proteome Systems Ltd (ASX:PXL) TDX Pending announced today that shareholders have voted in favour of an official name change to Tyrian Diagnostics Limited. The Company's ASX code will change to "TDX" on November 19, 2008. "Over...

  Tags: Proteome Systems Ltd.

• Examine the World Proteomics Market

  - 2008-09-10

  Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Proteomics Market http://www.reportlinker.com/p092466/World-Proteomics--Market.html This report analyzes the worldwide markets for Proteomics in Millions of US$. The major Product segments analyzed are Expression...

  Tags: Proteome Systems Ltd.

• Proteome Systems Raises $2.5 Million Through Private Placement

  - 2008-08-25

  SYDNEY, Australia -- Proteome Systems Ltd (ASX:PXL) today announced the successful closing of a private placement totalling $2.5 million AUD. The Company will issue 23,809,524 shares at A$0.105 per share. Participants in the placement include OppenheimerFunds and other US and Australian investors. Proceeds are being allocated to maintain development timelines...

  Tags: Proteome Systems Ltd.

• Proteome Systems Strengthens Focus on Diagnostics and Exits Therapeutics Business

  - 2008-08-22

  SYDNEY, Australia -- Proteome Systems Ltd (ASX:PXL) announced today it will cease active efforts to develop and commercialise a therapeutic compound portfolio acquired through the Company's 2005 merger with Eukarion, Inc. "Since my appointment as CEO, the management team has been dedicated to harnessing PXL's expertise in biomarker discovery and...

  Tags: Proteome Systems Ltd.

• Proteome Systems Reports Proof of Concept Study Results for Prostate Cancer Diagnostic Program

  - 2008-07-16

  SYDNEY, Australia -- Proteome Systems Limited (ASX Code:PXL) announced today that it has ceased development of a diagnostic test for Prostate Cancer. This decision is based on the results of a Proof of Concept study that demonstrated the project did not satisfy internal assessment hurdles. Following validation by Proteome...

  Tags: Proteome Systems Ltd.

• In April, Proteome Systems sold the rights to its Chemical Inkjet Printer and Xcise automated gel processing platform

  - 2007-07-15

  In April, Proteome Systems sold the rights to its Chemical Inkjet Printer and Xcise automated gel processing platform to Shimadzu in exchange for cash and the provision of Shimadzu MS and protein separation technologies.

  Tags: Proteome Systems Ltd.

• Proteome Systems Announces Deal Worth $5 Million With 10% Equity Stake in New U.S. Firm - Backed by Founders of Impax Laboratories, Athena Diagnostics, and Ivax Pharmaceuticals

  - 2007-05-07

  For Development of Cosmeceutic and Therapeutic Treatments for Dermatological Disease BOSTON -- Proteome Systems Ltd. (ASX:PXL) an Australian company with offices in Boston, MA, announced at BIO 2007 a significant licensing and commercialisation opportunity for its Eukarion topical compounds. PXL has agreed to partner with a new venture,...

  Tags: Athena Diagnostics Inc., Proteome Systems Ltd.

• Under an expanded cooperative marketing agreement, Proteome Systems will provide Agilent

  - 2006-10-15

  Under an expanded cooperative marketing agreement, Proteome Systems will provide Agilent with glycomics applications and software development.

  Tags: Proteome Systems Ltd.

• US and Australian Biotechs Collaborate to Develop New Semen-Based Non-Invasive Prostate Cancer Test; Prostate Cancer Associated Biomarker Identified by Proteome Systems Just Days Prior to Prostate Cancer Awareness Month

  - 2006-09-06

  BOSTON -- Just days prior to Prostate Cancer Awareness Month (September 2006) a leading biotech team developing a semen-based prostate cancer test -- designed to improve on the accuracy of the prostate-specific antigen PSA test -- has identified a prostate cancer biomarker associated with Human Carcinoma-Antigen HCA. When present along...

  Tags: Proteome Systems Ltd.

• Agilent Technologies Partners With Proteome Systems for Glycomics Applications, Software Development; Collaboration to Hasten Drug & Diagnostic Marker Discovery

  - 2006-08-09

  SYDNEY, Australia & PALO ALTO, Calif. -- Proteome Systems Ltd. (ASX:PXL), the globally recognized discovery, diagnostics and drug development company, and Agilent Technologies Inc. (NYSE:A) today announced the expansion of their cooperative marketing agreement to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics...

  Tags: Agilent Technologies Inc., collaboration, software, software development